预约演示
更新于：2026-02-27
Navepdekinra
更新于：2026-02-27
概要
基本信息
非在研机构 |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H48FN7O4 |
InChIKeyWEXJUHWVWXUMKQ-GVIAMBBFSA-N |
CAS号2467732-66-5 |
关联
5
项与 Navepdekinra 相关的临床试验NCT06092931
A Phase 1, Single-Center, Open-Label, Fixed-Sequence Study to Evaluate the Effect of DC-806 on the Single Dose Pharmacokinetics of CYP450 Enzyme and Transporter Substrates in Healthy Participants
NCT06045000
A Phase 1 Study to Assess the Excretion Balance, Pharmacokinetics, and Metabolism of [14C]-DC-806 in Healthy Male Participants
NCT05994807
A Phase 1, Single-Center, Open-Label, 2-Cohort, Fixed-Sequence, Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
100 项与 Navepdekinra 相关的临床结果
登录后查看更多信息
100 项与 Navepdekinra 相关的转化医学
登录后查看更多信息
100 项与 Navepdekinra 相关的专利（医药）
登录后查看更多信息
2
项与 Navepdekinra 相关的文献（医药）2025-05-01AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
Review
作者: Wu, Jashin J ; Kim, Dahyeon ; Babaei, Nickoulet ; Cervantes, Mireya ; Gill, Minka ; Yang, Seanna
Innovations in biologics are transforming the treatment of psoriatic diseases. The ability to target specific levels of immune activation provides a distinct advantage. Interleukin (IL)-17 inhibitors fall into this class of biologics, and they are effectively used to treat a spectrum of psoriatic diseases, such as psoriasis vulgaris and psoriatic arthritis. In recent years, anti-IL-17 agents have been the focus of therapeutic development, with various formulations and routes of administration. In this manuscript, we review pipeline anti-IL-17 therapies for psoriatic diseases identified through a search of ClinicalTrials.gov (January 2019-December 2024) and other databases. Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks.
PLoS One
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis
Article
作者: Huang, Kuan-Chieh ; Hunter, Hamish J A ; Lu, Timothy T ; Papp, Kim A ; Fatheree, Paul ; Warren, Richard B ; Rademacher, Peter M ; Jacobsen, John R ; Enejosa, Jeffrey V ; Kobel, Philip A ; Raha, Debasish ; Gordon, Kenneth B ; Batugedara, Hashini M ; Ghilardi, Nico ; Tang, Meina T ; Skinner, Craig
Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed. We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis. Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy. In the phase 1c trial, 32 patients consented to receive twice daily (BID) doses of placebo or DC-806 (200 mg or 800 mg) for 28 days. No serious adverse events (SAEs) or discontinuations due to treatment-related adverse events (TRAEs) occurred. In an exploratory analysis, adjusted mean percentage reductions from baseline in psoriasis area and severity indices (PASI) at Day 29 were 43.7%, 15.1%, and 13.3% for 800 mg BID, 200 mg BID, and placebo arms, respectively (800 mg BID vs placebo,
P
value = 0.0008). DC-806 was found to be well tolerated with an acceptable safety profile and preliminary signals of clinical efficacy in mild-to-moderate psoriasis. EudraCT Identifier: 2021-002888-21.
57
项与 Navepdekinra 相关的新闻（医药）2026-02-02
临床申请并购
2026-01-12
2026-01-12
100 项与 Navepdekinra 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 银屑病 | 临床2期 | 美国 | 2023-05-11 | |
| 斑块状银屑病 | 临床2期 | 美国 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 加拿大 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 捷克 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 德国 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 匈牙利 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 波兰 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 西班牙 | 2023-05-02 | |
| 斑块状银屑病 | 临床2期 | 英国 | 2023-05-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 229 | Placebo (Placebo) | 淵繭遞鬱襯遞廠鑰艱鏇 = 鹽憲憲淵簾膚獵繭醖製 襯鹹鹹廠選鑰醖膚顧顧 (襯淵憲鬱餘簾鏇鑰積顧, 襯獵鏇製艱襯齋齋繭衊 ~ 鹹願顧壓廠夢築觸繭簾) 更多 | - | 2025-04-04 | ||
(DC-806 200 mg BID) | 淵繭遞鬱襯遞廠鑰艱鏇 = 鏇齋廠夢簾夢網窪夢膚 襯鹹鹹廠選鑰醖膚顧顧 (襯淵憲鬱餘簾鏇鑰積顧, 醖憲遞顧築範蓋範醖觸 ~ 鏇鹽製願糧構憲廠構憲) 更多 | ||||||
临床1期 | 32 | DC-806 200 mg | 醖膚憲顧醖顧壓繭糧壓(糧鹽築簾選築鹹廠鏇製) = 壓夢夢鑰觸蓋衊糧願鏇 壓膚衊範衊構廠窪餘鹹 (製夢鑰壓蓋鬱製膚製憲 ) 更多 | 积极 | 2022-10-11 | ||
DC-806 800 mg | 醖膚憲顧醖顧壓繭糧壓(糧鹽築簾選築鹹廠鏇製) = 遞積觸觸遞繭鏇網鹹顧 壓膚衊範衊構廠窪餘鹹 (製夢鑰壓蓋鬱製膚製憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用